To include your compound in the COVID-19 Resource Center, submit it here.

Opening doors for I-O

Tumor lymphangiogenesis plus immunotherapy lets the right cells in

A Science Translational Medicine study has flipped the script for tumor lymphangiogenesis by turning VEGF-C, a hallmark of poor prognosis, into a biomarker and a target for successful responses to immunotherapies.

Tumors that are surrounded by a dense network of lymphatic vessels and express high levels of lymphangiogenesis-stimulating vascular endothelial growth factor C (VEGF-C) have been associated with metastasis and poor prognosis. Study author Manuel Fankhauser

Read the full 657 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers